burkitt lymphoma pathogenesis therapeutic targets structural functional genomics
burkitts lymphoma bl can often cured intensive chemotherapy toxicity therapy precludes use elderly patients endemic bl developing countries necessitating new strategies normal germinal centre b cell presumed cell origin bl diffuse large b-cell lymphoma dlbcl yet gene expression analysis suggests malignancies may use different oncogenic pathways bl subdivided sporadic subtype diagnosed developed countries epstein-barr-virus-associated endemic subtype hiv-associated subtype unclear whether subtypes use similar divergent oncogenic mechanisms used high-throughput rna sequencing rna interference screening discover essential regulatory pathways bl cooperate myc defining oncogene cancer % sporadic bl cases mutations affecting transcription factor tcf3 e2a negative regulator id3 fostered tcf3 dependency tcf3 activated pro-survival phosphatidylinositol--oh kinase pathway bl part augmenting tonic b-cell receptor signalling % sporadic bl cases oncogenic ccnd3 mutations produced highly stable cyclin d3 isoforms drive cell cycle progression findings suggest opportunities improve therapy patients bl
